Research Topics
| D VerthelyiSummaryAffiliation: Food and Drug Administration Country: USA Publications
| Collaborators
|
Detail Information
Publications
Disassociation of sex hormone levels and cytokine production in SLE patientsD Verthelyi
Retroviral Immunology Section, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
Lupus 10:352-8. 2001..Thus, while it remains possible that increased E2 and reduced DHEAS levels in lupus patients may help induce cytokine abnormalities early in disease, the subsequent cytokine imbalance does not correlate with sex hormone levels...
Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primatesMontserrat Puig
Laboratory of Immunology, Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
Nucleic Acids Res 34:6488-95. 2006..This technology fosters the development of more efficient immunotherapeutic oligonucleotide formulations for the treatment of allergies, cancer and infectious diseases...- Differential signaling by CpG DNA in DCs and B cells: not just TLR9Daniela Verthelyi
Division of Therapeutic Proteins, Center for Biologics Research and Evaluation, Food and Drug Administration, Bldg 29A Rm 3B19, 8800 Rockville Pike, Bethesda, MD 20892, USA
Trends Immunol 24:519-22. 2003..The different signaling complexes assembled might impact on the affinity with which CpG ODNs signal to TLR9 or activate additional pathways that lead to distinct immune responses... - Sex hormones as immunomodulators in health and diseaseD Verthelyi
Retroviral Immunology Section, Center for Biologics Evaluation and Research, Food and Drug Administration, Building 29A, Rm 3 D 2, Bethesda, MD 20892, USA
Int Immunopharmacol 1:983-93. 2001..Understanding the physiology of the interaction between sex hormones and immune function and its potential pathological consequences may provide insight into the autoimmune diseases and new directions for their treatment... - Female's heightened immune status: estrogen, T cells, and inducible nitric oxide synthase in the balanceDaniela Verthelyi
Laboratory of Immunology, Division of Therapeutic Proteins, Center for Drug Evaluation and Review, Food and Drug Administration, Bethesda, Maryland 20892, USA
Endocrinology 147:659-61. 2006 - CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infectionDaniela Verthelyi
Section of Retroviral Immunology and Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
J Immunol 170:4717-23. 2003..These findings support the clinical development of CpG ODNs as immunoprotective agents in normal and HIV-infected patients... - Human peripheral blood cells differentially recognize and respond to two distinct CPG motifsD Verthelyi
Section of Retroviral Research, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
J Immunol 166:2372-7. 2001..The distinct immunostimulatory properties of K and D ODN can improve the design of CpG-based products to achieve specific therapeutic goals... - Response of peripheral blood mononuclear cells from lupus patients to stimulation by CpG oligodeoxynucleotidesR A Zeuner
Center for Biologics Evaluation and Research/Food and Drug Administration, Bethesda, Maryland, USA
Rheumatology (Oxford) 42:563-9. 2003..CONCLUSION: Monocytes, dendritic cells and NK cells from SLE patients respond abnormally to CpG ODN stimulation, which may contribute to the cytokine imbalance observed in SLE... - CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cellsMayda Gursel
Section of Retroviral Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda 20892, USA
Eur J Immunol 32:2617-22. 2002..Since D type CpG motifs are present in bacterial and viral DNA, the maturation of monocytes into functional DC may reflect a physiologic response that can be harnessed therapeutically through the use of CpG ODN... - Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretionNora Katsenelson
Laboratory of Bacterial Polysaccharides, Division of Bacterial Parasitic and Allergenic Products, US Food and Drug Administration, Rockville, MD 20852 1448, USA
Eur J Immunol 37:1785-95. 2007..Thus, CpG ODN-induced increase in TACI expression is likely to play an important role in Ig secretion following activation of B lymphocytes through TLR9... - Adjuvant properties of CpG oligonucleotides in primatesDaniela Verthelyi
Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
Methods Mol Med 127:139-58. 2006..This work examines the progress in utilizing CpG ODN as adjuvants in conventional and DNA vaccines... - CpG oligodeoxynucleotides as vaccine adjuvants in primatesDaniela Verthelyi
Divisions of. Viral Products and Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research/Food and Drug Administration, Bethesda, MD 20892, USA
J Immunol 168:1659-63. 2002..These findings indicate that rhesus macaques provide a useful model for studying the in vivo activity of human CpG motifs, and that ODN expressing these motifs act as strong immune adjuvants... - Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifsBarbara Flynn
Division of Therapeutic Proteins, Center for Drug Evaluation and Review, Food and Drug Administration, Washington, D.C, USA
Infect Immun 73:4948-54. 2005..major treatment. Together, these findings support the development of clinical studies to assess the use of CpG ODN types D/A as immunoprotective and therapeutic agents... - Thermolytic CpG-containing DNA oligonucleotides as potential immunotherapeutic prodrugsAndrzej Grajkowski
Laboratory of Chemistry, Center for Drug Evaluation and Research, Food and Drug Administration 8800 Rockville Pike, Bethesda, MD 20892, USA
Nucleic Acids Res 33:3550-60. 2005.... - Use of CpG oligodeoxynucleotides as immune adjuvantsDennis M Klinman
Section of Retroviral Immunology, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
Immunol Rev 199:201-16. 2004..Ongoing clinical studies indicate that CpG ODNs are safe and well tolerated when administered as adjuvants to humans, and in some cases, they increase vaccine-induced immune responses... - CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaquesDaniela Verthelyi
Division of Therapeutic Proteins, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
AIDS 18:1003-8. 2004..CONCLUSIONS: These findings support the development of clinical studies to assess the use of CpG ODN as an adjuvant for HBV vaccination in healthy and immunocompromised HIV-infected subjects... - Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primatesDaniela Verthelyi
Division of Therapeutic Proteins, Food and Drug Administration, Building 29A Room 3B19, 8800 Rockville Pike, Bethesda, MD 20892, USA
Clin Immunol 109:64-71. 2003..In vivo studies in nonhuman primates indicate that proinflammatory or humoral immune responses can be selectively facilitated by judicious use of these distinct types of ODN... - CpG DNA: recognition by and activation of monocytesDennis M Klinman
Retroviral Immunology Section, Center for Biologics Evaluation and Research, FDA, Bldg 29A Rm 3 D 10, Bethesda, MD 20892, USA
Microbes Infect 4:897-901. 2002..ODNs of the "K"-type interact with Toll-like receptor 9 and induce monocytes to proliferate and secrete IL-6. In contrast, "D"-type ODNs trigger monocytes to differentiate into mature dendritic cells... - Immunotherapy with CpG oligonucleotides and antibodies to TNF-alpha rescues neonatal mice from lethal arenavirus-induced meningoencephalitisJoao A Pedras-Vasconcelos
Laboratory of Immunology, Division of Therapeutic Proteins, Office of Biotechnology, Center for Drug Evaluation and Review, FDA, Bethesda, MD 20892, USA
J Immunol 180:8231-40. 2008..To our knowledge, this is the first demonstration of the use of innate immune modulators plus Abs to TNF-alpha as therapeutics for a lethal neurotropic viral infection... - Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotidesCynthia A Leifer
Section of Retroviral Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
J Immunother (1997) 26:313-9. 2003..A mixture of ODNs with complementary activities induced significantly broader stimulation of donor PBMCs than any single ODN, providing a rational basis for proceeding into clinical trials with such a mixture... - Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durabilitySusana Mendez
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Infect Immun 71:5121-9. 2003..Our results suggest that immune modulation using CpG ODNs might be a practical approach to improving the safety of a highly effective live vaccine that has already been widely applied... - Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotideMayda Gursel
Section of Retroviral Research, Center for Biologics Evaluation and Research, Food and Drug Administration, Bldg 29A Rm 3D10, 8800 Rockville Pike, Bethesda, MD 20892, USA
J Leukoc Biol 71:813-20. 2002..Thus, different types of CpG ODN have distinct and in some cases incompatible effects on the same cells, a finding with important implications for the therapeutic use of these agents... - Design and development of thermolytic DNA oligonucleotide prodrugsAndrzej Grajkowski
Laboratory of Chemistry, Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
Ann N Y Acad Sci 1058:26-38. 2005.... - Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritisRainald A Zeuner
II Medical Clinic, University of Kiel, Kiel, Germany
Arthritis Rheum 48:1701-7. 2003..Current findings raise the possibility that suppressive ODNs may be useful in the prevention/treatment of proinflammatory diseases... - GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitisEugene D Ponomarev
Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI 53201, USA
J Immunol 178:39-48. 2007..These data also demonstrate that GM-CSF is a critical Th1 cell-derived cytokine required for the initiation of CNS inflammation associated with EAE, and likely MS... - Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotidesRainald A Zeuner
Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland, and Christian-Albrechts-University Kiel, Kiel, Germany
Arthritis Rheum 46:2219-24. 2002..Administering suppressive (but not control) ODN reduced the manifestations and severity of arthritis up to 80%. CONCLUSION: Suppressive ODN may be useful for the prevention or treatment of arthritis induced by bacterial DNA... - CpG oligodeoxynucleotides protect newborn mice from a lethal challenge with the neurotropic Tacaribe arenavirusJoao A Pedras-Vasconcelos
Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, Federal Drug Administration, Bethesda, MD 20892, USA
J Immunol 176:4940-9. 2006..To our knowledge, this is the first study assessing the mechanisms by which CpG ODN can protect mice from a neurotropic viral infection...